Post-operative adjuvant interferon-alfa-2B (intron-A) treatment after resection of thick primary melanoma and/or regional lymphnode metastases 'intermediate-high dose' vs intermediate-low dose' IFN-ALFA [interferon-alfa] vs observation: a 3-arm multicenter randomized phase III trial.

Trial Profile

Post-operative adjuvant interferon-alfa-2B (intron-A) treatment after resection of thick primary melanoma and/or regional lymphnode metastases 'intermediate-high dose' vs intermediate-low dose' IFN-ALFA [interferon-alfa] vs observation: a 3-arm multicenter randomized phase III trial.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2012

At a glance

  • Drugs Interferon alpha-2b (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top